r/PennyStocksWatch

Most people who followed $CYDY remember March 30, 2021. The FDA publicly stated that CytoDyn's claims about leronlimab were "misleading and not supported by the data", no benefit was shown in COVID-19 treatment trials. The stock dropped 25%+ that day.

What happened afterward was a class action lawsuit covering investors who held $CYDY between March 27, 2020 and March 30, 2022.

A $500,000 settlement has been reached and terms are now submitted to the court for approval.

Who qualifies?

Anyone who held $CYDY during the class period and suffered losses from the alleged misrepresentations about leronlimab's effectiveness for HIV and COVID-19.

Can I still apply?

Yes, you can submit your application now and it will be processed once claims filing officially opens after court approval.

If you were damaged by this don't forget to check your eligibility. GL!

Beyond Oil Successfully Completes Industrial-Scale Validation of Patented Chemistry, Demonstrating Substantial Reductions in Harmful Frying-Oil Degradation Compounds

Independent pilot at industrial food-production facility delivers approximately 93% reduction in Free Fatty Acids and approximately 52% reduction in Total Polar Compounds versus untreated control

Results extend Beyond Oil's validated technology into industrial frying amid tightening global regulation of frying-oil composition and worker exposure to frying-oil emissions

August 17, 2026 08:30 ET | Source: Beyond Oil Ltd.

VANCOUVER, British Columbia, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) ("Beyond Oil" or the "Company"), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, minimizing waste and enhancing sustainability, today announced the successful completion of an independent industrial-scale pilot validating its patented filter-powder technology at an industrial food-production facility. The pilot represents the first validated application of Beyond Oil's chemistry in the industrial-frying environment.

Key Results

• Approximately 93% reduction in Free Fatty Acids¹ versus the untreated control, with treated-oil quality remaining within a narrow, stable range across the full production cycle.
• Approximately 52% reduction in Total Polar Compounds² versus the untreated control, with the Beyond Oil-treated fryer remaining well below the 24% regulatory maximum³ throughout the pilot while the untreated control breached that threshold.
• Structured sensory-panel evaluation confirmed the Beyond Oil-treated product retained day-one characteristics across the full pilot period, with clearer and more golden oil, uniform crispness, consistent taste, and no burnt-oil or rancid odors.
• Materially reduced secondary odors in the plant environment during production, with direct implications for workplace conditions and worker exposure to frying-oil emissions over extended shifts.
• Integration with existing plant filtration infrastructure without requiring custom capital equipment, demonstrating operational compatibility of Beyond Oil's chemistry with standard industrial-frying environments.

Industrial pilot results: approximately 93% lower Free Fatty Acids and approximately 52% lower Total Polar Compounds versus untreated control. Source: Data derived from the industrial-scale pilot described in this news release; regulatory maximum reference (24% TPC) per academic and industry-standard sources (see footnote 1).

Jonathan Or, CEO of Beyond Oil, commented: "This pilot is a validation of what Beyond Oil's chemistry is fundamentally about - improving frying across every dimension that matters: food quality, health, worker safety, and sustainability. While our near-term commercial focus remains firmly on the expansion of our direct-sales footprint in the United States for our core foodservice business, this milestone reflects longer-horizon work we have been advancing in parallel - validating that the same patented chemistry performs at industrial scale and delivers the same core outcomes: substantially cleaner oil, safer and higher-quality fried product, and a materially healthier working environment for the people producing that food. It confirms that our technology addresses a system-level problem in how the world produces fried food, independent of customer type or scale of operation, and reinforces the long-term significance of the industrial-frying opportunity for Beyond Oil."

The industrial-frying segment is a large, growing global market. The North American frozen French fries market alone, for example, was valued at approximately US$6.8 billion in 2022 and is projected to reach approximately US$8.1 billion by 2028⁴, while the broader industrial-frying-machine market is projected to grow at a compound annual rate of approximately 7.4% from 2026 through 2034⁵. The performance validated in this pilot underscores the long-term significance of this opportunity for Beyond Oil as the Company continues its principal near-term focus on scaling its foodservice business in the United States.

The pilot was conducted over multiple production days at an industrial food-production facility. Beyond Oil's product was integrated into the plant's existing filtration workflow at end-of-day cycles: hot oil was transferred to an auxiliary mixing and settling tank, treated with a specialized industrial version of Beyond Oil's patented powder, and left overnight for phase separation. The following morning, the clean upper oil phase was returned to the fryer through the facility's standard filtration equipment; the settled powder phase, containing absorbed food particles and degradation compounds, was removed as a low-volume waste stream. An identical untreated fryer was operated in parallel as a control.

Emissions from high-temperature frying are formally classified by the International Agency for Research on Cancer as a Group 2A ("probably carcinogenic to humans") hazard⁶, and food-safety and occupational-health regulators across major markets have moved in recent years to tighten oversight of frying-oil composition, acrylamide levels in industrially-produced foods, and worker exposure to frying-oil emissions. Regulatory ceilings on Total Polar Compounds in frying oil are set at 24% to 25% across most major markets⁷, with enforcement activity rising in parallel. Beyond Oil's technology is designed to address these converging pressures directly, at the point of oil degradation itself, rather than downstream of it.

Free Fatty Acids and Total Polar Compounds are the two most widely monitored indicators of frying-oil degradation. Both are directly associated with the formation of compounds linked to health risks, including acrylamide, polycyclic aromatic hydrocarbons, and trans fats, which accumulate in oil as it degrades and reach both consumers (absorbed into fried food) and production personnel (inhaled as vapor or absorbed through skin exposure). The stability observed in the Beyond Oil-treated fryer across the pilot period reflects consistent oil quality maintained across multiple production cycles - a materially different outcome from the accelerating degradation curve observed in the untreated control.

About Beyond Oil Ltd.

We all love fried food. Let's make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company's patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil's solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

---

[...] Read the full release here: https://www.globenewswire.com/news-release/2026/08/17/3346080/0/en/beyond-oil-successfully-completes-industrial-scale-validation-of-patented-chemistry-demonstrating-substantial-reductions-in-harmful-frying-oil-degradation-compounds.html

I let ChatGPT support me in review for typo and grammar fault and review

Transcript source: https://finance.yahoo.com/quote/MDAI/earnings/MDAI-Q2-2026-earnings_call-648313.html

- BARDA is underwriting the first 30 U.S. DeepView placements — these are intended for routine use across burn centers, trauma centers and ERs through June 30, 2027. See transcript time 08:03–09:08 & 14:25

- Hospital procurement has already started. Spectral is leveraging its existing relationships with clinical-study sites and KOLs (Key Opinion Leader)*, where management expects procurement to move faster. See transcript 0:24:00

-Some installations are expected already in Q4 2026. Management said it is working toward installations at both previous clinical sites and additional sites. See transcript time 21:15

- The business model is more interesting than just selling devices: capital purchase/lease + recurring software and services with a minimum 3-year term for each installation. See transcript time 08:03 & 14:25

- Pricing work is already done. A third-party pricing study plus preliminary customer discussions indicate commercial pricing could support margins well above current BARDA/R&D margins. See transcript time 15:25

- UK/Australia could be next. Management sees previous evaluation sites in Australia and one or two UK centers as likely early international adopters, potentially still in 2026. See transcript time 27:22

- Main near-term risk = procurement speed. New hospitals may require not only normal procurement approval but also cybersecurity and AI committee reviews. Management openly acknowledged this could lengthen the sales cycle.
See transcript time 26:01

*In medtech, a KOL is typically a highly respected physician, surgeon, researcher, or clinical specialist whose opinions influence other clinicians and hospitals.

In Spectral AI’s case, management said they have strong relationships with KOLs in the burn-care community from their previous clinical studies.

So when Capone says “we have strong KOLs,” he’s essentially saying Spectral already has influential clinicians familiar with DeepView who can help drive early adoption.

For a new medtech product, strong KOL support can be extremely valuable, especially when selling into a relatively concentrated specialist market such as U.S. burn centers.